CompletedPHASE1, PHASE2NCT06000514

Topical Sm29 in Combination With Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis.

Studying Leishmaniasis

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Hospital Universitário Professor Edgard Santos
Principal Investigator
SERGIO C OLIVEIRA, PhD
Federal University of Minas Gerais
Intervention
Sm29 Protein, Schistosoma Mansoni(drug)
Enrollment
20 target
Eligibility
18-50 years · All sexes
Timeline
20192022

Study locations (1)

Collaborators

Conselho Nacional de Desenvolvimento Científico e Tecnológico · Oswaldo Cruz Foundation

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06000514 on ClinicalTrials.gov

Other trials for Leishmaniasis

Additional recruiting or active studies for the same condition.

See all trials for Leishmaniasis

← Back to all trials